Bianca Weinstock-Guttman

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

Marco Rovaris, Bianca Weinstock-Guttman, M. Rovaris, 2016, The Cochrane database of systematic reviews.

Cost-effectiveness of disease-modifying therapy for multiple sclerosis

S. Schwid, Alina Bajorska, Bianca Weinstock-Guttman, 2011, Neurology.

Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

J. Lechner-Scott, M. Slee, A. Ponsonby, 2023, Journal of neurology.

Increased intraindividual variability (IIV) in reaction time is the earliest indicator of cognitive change in MS: A two-year observational study

L. Charvet, J. Ness, S. Mar, 2024, International journal of clinical and health psychology : IJCHP.

Post-Partum Clinical and Patient-Reported Outcome Changes in Mothers with Multiple Sclerosis: Findings from the NAPPREMS Study

D. Jakimovski, S. Eckert, D. Hojnacki, 2024, Medicina.

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

C. Boz, Chao Zhu, S. Ozakbas, 2024, Journal of neurology, neurosurgery, and psychiatry.